Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
Primo N. Lara(UC Davis Comprehensive Cancer Center), Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Mark J. McKeage(University of Auckland), Martin Reck(German Center for Lung Research), Abderrahim Fandi(Heidelberg University), György Losonczy(Chinese University of Hong Kong), István Albert(Alleanza Contro il Cancro), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Xiaolin Fan(Novartis (United States)), Dae Seog Heo(Seoul National University), Jean‐Yves Douillard(Integrated Oncology (United States)), Joachim von Pawel(Asklepios Fachkliniken München-Gauting)
Cited by 320
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k